Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 3-undersøgelse om effektiviteten og sikkerheden af ​​humant plasma-afledt antithrombin (Atenativ) hos heparin-resistente patienter, der er planlagt til at gennemgå hjertekirurgi, hvilket nødvendiggør kardiopulmonal bypass

23. september 2026 opdateret af: Octapharma

Fase 3, dobbeltblind, placebokontrolleret, multicenterundersøgelse af effektiviteten og sikkerheden af ​​humant plasma-afledt antithrombin (Atenativ) hos heparinresistente patienter, der er planlagt til at gennemgå hjertekirurgi, der nødvendiggør kardiopulmonal bypass

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • British Columbia
      • New Westminster, British Columbia, Canada, V3L0A4
        • Rekruttering
        • Royal Columbian Hospital
    • Ontario
      • Kingston, Ontario, Canada, K7L2V7
        • Rekruttering
        • Kingston Health Sciences Centre
      • Toronto, Ontario, Canada, M5G2C4
        • Ikke rekrutterer endnu
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canada, H1T1C8
        • Rekruttering
        • Montreal Heart Institute
      • Cambridge, Det Forenede Kongerige
        • Rekruttering
        • Royal Papworth Hospital
      • Coventry, Det Forenede Kongerige
        • Rekruttering
        • University Hospital Coventry and Warwickshire
      • Middlesbrough, Det Forenede Kongerige
        • Rekruttering
        • The James Cook University Hospital
    • California
      • Stanford, California, Forenede Stater, 94305-5101
        • Rekruttering
        • Stanford University School of Medicine
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710-1000
        • Rekruttering
        • Duke University Medical Center
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Rekruttering
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic
      • Columbus, Ohio, Forenede Stater, 43214
        • Rekruttering
        • The Ohio State University
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • OU Health University of Oklahoma Medical Center
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
        • Rekruttering
        • University of Texas Southwestern Medical Center
      • Reims, Frankrig
        • Afsluttet
        • CHU de Reims, Hôpital Robert Debré
      • Rennes, Frankrig
        • Trukket tilbage
        • CHU de Rennes
      • Kaunas, Litauen
        • Afsluttet
        • Hospital of Lithuanian university of Health sciences Kauno Klinikos
      • Vilnius, Litauen
        • Rekruttering
        • Vilnius University hospital Santaros Klinikos
      • Bucharest, Rumænien
        • Rekruttering
        • Institute for Cardiovascular Diseases C.C. Iliescu
      • Kamenitz, Serbien
        • Rekruttering
        • Institute of Cardiovascular Diseases Vojvodina
      • Ljubljana, Slovenien
        • Rekruttering
        • University Medical Centre Ljubljana
      • Brno, Tjekkiet
        • Rekruttering
        • Center of Cardiovascular and Transplant Surgery
      • Prague, Tjekkiet
        • Afsluttet
        • Institute for Clinical and Experimental Medicine
      • Innsbruck, Østrig
        • Rekruttering
        • University Hospital Innsbruck
      • Vienna, Østrig
        • Rekruttering
        • Vienna General Hospital AKH, Medical University of Vienna

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Planned cardiac surgery with CPB
  2. Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
  3. Patients between 18 and 85 years of age, inclusive
  4. Freely given written or electronic informed consent
  5. In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery

Exclusion Criteria:

  1. Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:

    1. vitamin K antagonists (within 3 days)
    2. direct oral anticoagulants (within 2 days)
    3. thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    4. ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    5. glycoprotein IIb/IIIa antagonist (within 24 hours)
  2. Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)

  3. Renal insufficiency, defined as serum creatinine level >2.0 mg/dL

  4. Thrombocytosis, defined as platelet count >400,000 per μL

  5. Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid

  6. History of anaphylactic reaction(s) to blood or blood components

  7. Refusal to receive transfusion of blood or blood-derived products

  8. Current participation in another interventional clinical trial or previous participation in the current trial

  9. Treatment with any IMP within 30 days prior to screening visit

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low-dose Atenativ

Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Eksperimentel: High-dose Atenativ

Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Placebo komparator: Placebo

Patients will receive a saline bolus dose

Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Restoring heparin responsiveness
Tidsramme: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Amounts of further therapy for restoring heparin responsiveness
Tidsramme: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Change in activated clotting time (ACT) values
Tidsramme: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion

The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo

Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
Change in antithrombin plasma levels
Tidsramme: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion

The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo

Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
Change in heparin usage
Tidsramme: From end of IMP infusion to the end of surgery

The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo

From end of IMP infusion to the end of surgery
FP unit use
Tidsramme: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first

The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Tidsramme: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first

The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first)

From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
Transfusion of allogenic blood products
Tidsramme: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of coagulation factor concentrates
Tidsramme: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of other haemostatic-relevant therapies
Tidsramme: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Postoperative chest tube drainage
Tidsramme: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first

From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
Need for reoperation due to bleeding
Tidsramme: 24 hours after the start of IMP infusion

Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical)

24 hours after the start of IMP infusion
Cell saver volume
Tidsramme: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between cell saver volume until the end of surgery

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Adverse events
Tidsramme: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first

Incidence of adverse events, including all related and non-related, non-serious adverse events

From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
Serious adverse events
Tidsramme: From the start of IMP infusion until 28 days after IMP administration

Incidence of serious adverse events

From the start of IMP infusion until 28 days after IMP administration
Survival status
Tidsramme: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration

Number of patients surviving in all three cohorts

At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
Red Blood Cell count
Tidsramme: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
White Blood Cell count
Tidsramme: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haemoglobin levels
Tidsramme: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haematocrit
Tidsramme: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
Platelet count
Tidsramme: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. august 2024

Primær færdiggørelse (Anslået)

1. marts 2028

Studieafslutning (Anslået)

1. marts 2028

Datoer for studieregistrering

Først indsendt

17. oktober 2023

Først indsendt, der opfyldte QC-kriterier

17. oktober 2023

Først opslået (Faktiske)

23. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner